BioWorld

Jan. 4, 2002

BioCryst Gets Flu Drug Back On Track, Resumes Enrollment

BioCryst Pharmaceuticals Inc. started out the flu season earlier this week by commencing Phase III enrollment in the United States for its flu treatment, peramivir, after getting clearance from the FDA to resume the study. Read More

Neurocrine, Taisho Start Pivotal Study Of Diabetes Candidate

Too Much p53 Tumor Suppressor Activity Hastens Symptomatology Of Advanced Senescence In Mice

Rib-X Raises $22M In Series A To Develop Anti-Infective Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...